trending Market Intelligence /marketintelligence/en/news-insights/trending/oYjj_mypLOb0gWUUHQOhig2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Theralase raises C$1.4M to fund bladder cancer therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Theralase raises C$1.4M to fund bladder cancer therapy

Theralase Technologies Inc. closed a private placement of stock and warrant units to raise about C$1.4 million in gross proceeds, which will be used to develop a bladder cancer treatment.

The Toronto-based healthcare company sold 4,095,157 units priced at 35 Canadian cents apiece in the offering. Theralase Technologies will use the proceeds from the sale to develop its bladder cancer therapy as well as for working capital and general corporate purposes.

Each unit in the offering is made up of 1 common share of Theralase Technologies and a warrant to purchase 1 common share for 50 cents each within 24 months.

Theralase Technologies develops laser technology platforms to destroy cancer cells and treat other diseases.